Hyperpolarized Magnetic Resonance Imaging, Nuclear Magnetic Resonance Metabolomics, and Artificial Intelligence to Interrogate the Metabolic Evolution of Glioblastoma
Metabolites · 14.08.2024 · 14 (8) · 448
DOI: 10.3390/metabo14080448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolites, online erschienen am 14.08.2024. Verfasst von Kang Lin Hsieh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIBIB NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Glioblastoma (GBM) is a malignant Grade VI cancer type with a median survival duration of only 8–16 months. Earlier detection of GBM could enable more effective treatment. Hyperpolarized magnetic resonance spectroscopy (HPMRS) could detect GBM earlier than conventional anatomical MRI in glioblastoma murine models. We further investigated whether artificial intelligence (A.I.) could detect GBM earlier than HPMRS. We developed a deep learning model that combines multiple modalities of cancer data to predict tumor progression, assess treatment effects, and to reconstruct in vivo metabolomic information from ex vivo data. Our model can detect GBM progression two weeks earlier than conventional MRIs and a week earlier than HPMRS alone. Our model accurately predicted in vivo biomarkers from HPMRS, and the results inferred biological relevance. Additionally, the model showed potential for examining treatment effects. Our model successfully detected tumor progression two weeks earlier than conventional MRIs and accurately predicted in vivo biomarkers using ex vivo information such as conventional MRIs, HPMRS, and tumor size data. The accuracy of these predictions is consistent with biological relevance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Computer Science, Louisiana State University, Baton Rouge, LA 70803, USA.
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Health Data Science and Artificial Intelligence, McWilliams School of Biomedical Informatics at UTHealth Houston, Houston, TX 77030, USA.
- Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Kang Lin Hsieh, Travis C Salzillo, Pratip K Bhattacharya
Förderung
- NCI NIH HHS
- NIBIB NIH HHS
- NCATS NIH HHS
- Cancer Prevention and Research Institute of Texas
- NIA NIH HHS
- CPRIT Research Training Award
- The University of Texas Health Science Center at Houston Center for Clinical and Translational Sciences TL1 Program
- CPRIT Scholar in Cancer Research
Zitieren
APA
Hsieh, K. L., Chen, Q., Salzillo, T. C., Zhang, J., Jiang, X., Bhattacharya, P. K., & Shams, S. (2024). Hyperpolarized Magnetic Resonance Imaging, Nuclear Magnetic Resonance Metabolomics, and Artificial Intelligence to Interrogate the Metabolic Evolution of Glioblastoma. Metabolites, 14(8), 448. https://doi.org/10.3390/metabo14080448
Vancouver
Hsieh KL, Chen Q, Salzillo TC, Zhang J, Jiang X, Bhattacharya PK, et al. Hyperpolarized Magnetic Resonance Imaging, Nuclear Magnetic Resonance Metabolomics, and Artificial Intelligence to Interrogate the Metabolic Evolution of Glioblastoma. Metabolites. 2024;14(8):448. doi:10.3390/metabo14080448
BibTeX
@article{Hsieh2024,
author = {Hsieh, Kang Lin and Chen, Qing and Salzillo, Travis C and Zhang, Jian and Jiang, Xiaoqian and Bhattacharya, Pratip K and Shams, Shyan},
title = {Hyperpolarized Magnetic Resonance Imaging, Nuclear Magnetic Resonance Metabolomics, and Artificial Intelligence to Interrogate the Metabolic Evolution of Glioblastoma},
journal = {Metabolites},
year = {2024},
volume = {14},
number = {8},
pages = {448},
doi = {10.3390/metabo14080448}
}
EUVIMED